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Abstract
Background: Avian influenza viruses (AIV) cause high morbidity and mortality among the poultry
worldwide. Their highly mutative nature often results in the emergence of drug resistant strains,
which have the potential of causing a pandemic. The virus has two immunologically important
glycoproteins, hemagglutinin (HA), neuraminidase (NA), and one ion channel protein M2 which are
the most important targets for drug discovery, on its surface. In order to identify a peptide-based
virus inhibitor against any of these surface proteins, a disulfide constrained heptapeptide phage
display library was biopanned against purified AIV sub-type H9N2 virus particles.
Results: After four rounds of panning, four different fusion phages were identified. Among the
four, the phage displaying the peptide NDFRSKT possessed good anti-viral properties in vitro and
in ovo. Further, this peptide inhibited the hemagglutination activity of the viruses but showed very
little and no effect on neuraminidase and hemolytic activities respectively. The phage-antibody
competition assay proved that the peptide competed with anti-influenza H9N2 antibodies for the
binding sites. Based on yeast two-hybrid assay, we observed that the peptide inhibited the viral
replication by interacting with the HA protein and this observation was further confirmed by co-
immunoprecipitation.
Conclusion: Our findings show that we have successfully identified a novel antiviral peptide against
avian influenza virus H9N2 which act by binding with the hemagglutination protein of the virus. The
broad spectrum activity of the peptide molecule against various subtypes of the avian and human
influenza viruses and its comparative efficiency against currently available anti-influenza drugs are
yet to be explored.
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Background
Avian influenza A viruses (AIV) are enveloped, segmented
and negative-stranded RNA viruses, that circulate world-
wide and cause one of the most serious avian diseases
called Bird Flu, with severe economic losses to the poultry
industry [1]. They are divided into different subtypes
based on two surface glycoproteins, hemagglutinin (HA)
and neuraminidase (NA). Currently, there are 16 different
types of HA and nine different types of NA circulating
among aquatic birds [2]. Although wild birds and domes-
tic waterfowls are considered natural reservoirs for all sub-
types, they usually do not show any symptoms of the
disease. Domestic birds such as chickens are main victims
of this virus especially of H5, H7 and H9 subtypes. The
H9N2 viruses are endemic and highly prevalent in poultry
of many Eurasian countries. These viruses cause severe
morbidity and mortality in poultry as a result of co-infec-
tion with other pathogens [3,4]. Recent studies have also
shown that H9N2 prevalence in poultry pose a significant
threat to humans [5-8].
Adamantane derivatives (amantadine and rimantadine)
and neuraminidase inhibitors (NAIs; zanamivir and osel-
tamivir) are currently used for the chemoprophylaxis and
treatment of influenza [9]. The drugs should be adminis-
tered within 48 hours of infection to get the optimum
results. Amantadine binds to and blocks the M2 ion chan-
nel proteins function and thereby inhibits viral replica-
tion within infected cells [10]. NAIs inhibit the activity of
neuraminidase enzymes and thus prevent the exit of virus
from the infected cells [11].
In the last 15 years, the rate of amantadine resistant strains
has risen from 2% during 1995 – 2000 to an alarming
92.3% in the early 2006 in the United States alone for the
H3N2 subtype [12] although none of the neuraminidase
inhibitors and adamantane resistant H5N1 viruses were
reported in the south east asian region from 2004 to 2006
[13]. Usually, these viruses are highly pathogenic and
transmissible among animals [14,15]. The viruses resist-
ant to these drugs emerge due to mutations either at active
sites of NA, altering its sensitivity to inhibition, or a muta-
tion in the HA [9]. The mutations at HA reduce the affinity
of the proteins to the cellular receptors and enable the
virus to escape from infected cells without the need of NA.
In several instances, strains which were resistant to both
classes of antiviral drugs have been isolated from patients
[16-18]. For these reasons, it has become necessary to
identify novel drugs against the virus to control and treat
infections.
Traditionally, the generation of new drugs involves
screening hundreds of thousands of components against
desired targets via in vitro screening and appropriate in vivo
activity assays. Currently, new library methodologies have
been developed with alternative and powerful strategies,
which allow screening billions of components with a fast
selection procedure to identify most interesting lead can-
didates. In this present study we used one of such meth-
odologies called phage display technology to select novel
peptides against avian influenza virus H9N2. The selected
peptides were characterised for their anti-viral properties
and their interaction site with the virus was identified by
yeast two-hybrid assay and co-immunoprecipitation. The
results showed that one of the peptides possesses good
anti-viral property and inhibits the viral replication by
binding with HA protein. The broad range anti-viral activ-
ity of the peptide against various subtypes of the virus is
yet to be studied and if it turned positive, the peptide may
serve as an alternative anti-viral agent to replace current
potentially inefficient drugs.
Results
Selection of peptides that interact with AIV
Peptides selected from phage display library have been
used as effective anti-microbial agents in previous studies
[19]. In this study, a 7-mer constrained phage displayed
random peptide library containing about 3.7 × 109 differ-
ent recombinant bacteriophages were used to select lig-
ands that interact with the purified target molecule, AIV
subtype H9N2. Four rounds of panning were carried out,
each with a slight increase in stringency to isolate high-
affinity peptide ligands.
Table 1 shows the heptapeptide sequences obtained from
four rounds of panning the peptide library against AIV
subtype H9N2. Seventeen out of 35 phages analysed from
the fourth round represented the sequence NDFRSKT and
other major sequences found in the final round of pan-
ning were LPYAAKH and ILGDKVG. A new sequence car-
rying the peptide QHSTKWF emerged during the fourth
round of panning represented 10% of the total phages
sequenced.
Biopanning of the phage library against streptavidin (the
positive control) gave a consensus sequences containing
HPQ motif which totally represented 82% of the total
phages screened from the third round of panning and
these results are in good agreement to the reported find-
ings [20-22]. No recognisable consensus sequence was
observed with BSA, which served as a negative control.
The peptide NDFRSKT was named as P1 (C-P1 – cyclic
form; L-P1 – Linear form; FP-P1 – fusion phage displaying
this peptide).
Estimation of binding abilities of selected phage clones
Recombinant phages selected from the fourth round of
panning were further analysed for their binding specificity
by phage-ELISA which was carried out with all the four
recombinant phages in varying phage concentrationsVirology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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against two different virus concentrations (5 μg and 10
μg/100  μl). The results (Figure 1) showed that all the
phages selected from the biopanning were able to bind
the virus efficiently and the higher the concentration of
the recombinant phages, the higher the signal irrespective
of the concentration of the virus.
Antiviral activity of peptides and fusion phages in vitro
The fusion phage FP-P1 and the cyclic as well as linear
peptides were evaluated for its ability to inhibit viral-
induced cell death using a cytotoxicity assay as explained
by Jones et al (2005). Briefly, MDCK cells were mock inoc-
ulated (medium alone) or inoculated with different con-
centrations of phage or peptide treated AIV virus (MOI of
0.05 pfu/cell), and cell viability was evaluated at 48 hpi. If
the FP-P1 phages were able to inactivate the AIV, then the
AIV might not be able to induce the cell death and so the
viability will increase. Interestingly, pre-treatment with
increasing concentration of FP-P1 as well as the peptides
increased the cell viability in dose dependent manner.
More than 100% increase in viability was observed with
the fusion phage and peptide treatment. In contrast, treat-
ment with the wild type phage and control peptides did
not show any significant increase in viability (Figure 2 and
3). This observation demonstrates that the fusion phage
FP-P1 as well as the peptides (both in linear as well as
cyclic form) was capable of inactivating the virus or inhib-
iting the viral replication in vitro.
Antiviral activity of peptides and fusion phages in ovo
Peptides were evaluated for their antiviral activity in ovo
against AIV H9N2. Briefly, different concentrations of
Table 1: Heptapeptides binding to AIV subtype H9N2 and streptavidin selected from the phage display random peptide library.
Rounds of panning Heptapeptide sequences Frequency of sequences (%)
4th round NDFRSKT 47
QHSTKWF 10.5
LPYAAKH 5
ILGDKVG 5
Unrelated sequences 23
Panning of Streptavidin
3rd round Streptavidin HPQFLSL 55
GLYNHPQ 27
Unrelated sequences 18
After 4 rounds of selection and amplification 20, 35 and 35 individual clones from the 2nd, 3rd and 4th rounds, respectively, were sequenced for AIV 
whereas 20 clones were sequenced from the 3rd round of panning against Streptavidin.
Binding ability of all four recombinant phages to AIV H9N2 Figure 1
Binding ability of all four recombinant phages to AIV 
H9N2. Briefly, viruses were coated in the microwell plate at 
two different concentrations (5 μg and 10 μg/ml; 200 μl) and 
were detected by two different concentrations of recom-
binant phage molecules (1012 pfu/ml and 1011 pfu/ml). Dotted 
bars represent the 5 μg of target whereas solid bars repre-
sent 10 μg of target. All the four types of recombinant phage 
particles could able to detect the target AIV. Wild type phage 
M13 was used as control (Data not shown to avoid complex-
ity of the graph). A – ILGDKVG (5%), B – NDFRSKT (47%), 
C – LPYAAKH (23%), D – QHSTKWF (5%), Blue Square – 
1011 pfu/ml, Grey Square-1012 pfu/ml
Antiviral activity of peptides in vitro Figure 2
Antiviral activity of peptides in vitro. MDCK cells were 
inoculated with untreated AIV H9N2 or treated with 
increasing concentration of linear, cyclic and control peptides 
and the cell viability was determined by MTT assay. Results 
shown are the mean of three trials +/- SD. (*, statistical sig-
nificance (P < 0.05)Virology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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both cyclic and linear peptides (0.00, 0.001, 0.01, 0.1 and
1 mM) were mixed with constant amount of virus (8
HAU) and injected into allantoic cavity of embryonated
chicken eggs. After 3 days, the allantoic fluid was har-
vested and the HA titer was determined. Complete inhibi-
tion was observed at the concentration 1 mM (Figure 4).
The IC50 values of both cyclic and linear peptides were 48
μM and 71 μM respectively.
To evaluate the efficacy of the fusion phage to inhibit the
virus propagation in ovo, different pfu (108 – 1013/100 μl)
of recombinant fusion phages were mixed with constant
amount of virus (16 HAU) and injected into the allantoic
cavity of embryonated chicken eggs. After 3 days, the
allantoic fluid was harvested and the HA titer was meas-
ured. The fusion phage FP-P1 reduced the viral titer in the
allantoic fluid upto 4 fold at the concentration more than
1013 pfu/100 μl (Figure 5). Based on the dose response
curve, the IC50 for FP-P1 was approximately 5 × 1011 pfu/
100 μl.
Besides, to determine whether these peptides inhibit the
virus replication specifically, these peptides (linear, cyclic
and FP-P1) were tested for inhibitory effects against NDV
strain AF2240. None of these molecules do not posses sig-
nificant (ANOVA, p = 0.596) inhibitory effect against
NDV replication (Figure 6).
Inhibitory effects of peptides and fusion phages on virus 
adsorption onto chicken red blood cells (cRBCs)
Influenza A viruses, including AIV sub-type H9N2, have
the ability to adsorb onto chicken RBCs, resulting in
hemagglutination. So, inhibition of agglutination of
blood cells was used to test the hypothesis that peptides
C-P1, L-P1 and fusion phage FP-P1 inhibited viral attach-
ment. Initially, the inhibition of viral-induced agglutina-
tion of cRBCs by the peptides and fusion phages were
monitored. Twofold dilutions of untreated or peptide/
phage treated virus were incubated with cRBCs, and agglu-
tination was observed. All the three forms of peptides
completely inhibited AIV sub-type H9N2 agglutination in
a dose-dependent manner at concentrations of 100 μM or
more (Table 2). In contrast, the control peptide CSWGEY-
DMC had no effect on agglutination.
Inhibitory effects of peptides and fusion phages on 
neuraminidase activity
Based on the ability of the peptides and fusion phage to
inhibit viral attachment, we hypothesised that the peptide
interacted either with NA or HA since changes to either
surface glycoproteins can alter fitness of the virus. Moreo-
Antiviral activity of fusion phages in vitro Figure 3
Antiviral activity of fusion phages in vitro. MDCK cells 
were inoculated with untreated virus (AIV H9N2) or virus 
treated with increasing concentration of fusion phages and 
the cell viability was determined by MTT assay. Results 
shown are the mean of three trials +/- SD.
Antiviral activity of peptides in ovo Figure 4
Antiviral activity of peptides in ovo. The peptide con-
centration needed to inhibit 50% of the virus growth was 
determined using different concentrations of peptides. 
Experiments were done in triplicates and the error bars rep-
resent the standard error of the mean. *, statistical signifi-
cance (P < 0.05) (The SEM value is not shown for other 
values as there was little variation between repeated experi-
ments).
Antiviral activity of fusion phages in ovo Figure 5
Antiviral activity of fusion phages in ovo. The fusion 
phage concentration needed to inhibit 50% of the virus 
growth was determined using different concentrations of 
recombinant phages FP-P1. Experiments were done in tripli-
cates and the error bars represent the standard error of the 
mean. *, statistical significance (P < 0.05) (The SEM value is 
not shown for some data as there was no variation between 
repeated experiments).Virology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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ver, the biopanning experiment was carried out against
the whole virus. As NA is one of the most abundant sur-
face glycoproteins, the chances for binding of the peptides
to this protein are relatively high. To determine if peptides
or fusion phage inhibited enzymatic activity, untreated or
peptide/fusion-phage – treated virus was tested for enzy-
matic activity. Untreated and cyclic peptide or fusion
phage treated virus had similar enzymatic activity, sug-
gesting that both of them had no effect on NA activity. But
linear peptide showed reduced Neuraminidase activity at
very very high concentrations. 1000 μM or more concen-
tration of the linear peptide was required to reduce
around 35% of the enzyme activity (data not shown).
Considering the inability of cyclic and FP-P1 to inhibit the
NA activity and the very limited ability of linear peptide it
can be deduced that the linear peptide may non-specifi-
cally interact with the NA protein, perhaps taking advan-
tage of its flexible nature.
Inhibition of phage binding to AIV by antibody
Polyclonal antibody (pAb) and phage competition assay
was performed to understand whether they both share
common binding sites. Briefly, either fusion phages alone
or fusion phage-antibody mixtures were added into wells
coated with the virus and the eluted phages were titered.
Figure 7 demonstrates that the fusion phages FP-P1 were
able to compete with the pAb for binding sites on AIV. In
the presence of the antibody, the number of phages
bound to the AIV coated wells reduced dramatically as a
result of the competition between these two molecules for
the same binding site on AIV. For example, at input pfu of
1 × 1012/100 μl, the output pfu for the FP-P1 phage alone
was 1.8 × 104 plaques but in the presence of pAb, the out-
put was reduced to 7.5 × 103 plaques, which is almost 2.4-
fold reduction. This result clearly shows us that the phage
molecules that display peptides on their surface can com-
pete for the epitope binding sites on AIV with polyclonal
antibodies.
Peptide-phage competition assay
In order to identify whether the synthetic peptides and the
phages (FP-P1) compete for the same binding sites on AIV
H9N2, a peptide-phage competitive assay was performed.
When the peptides (both linear and cyclic) were pre-incu-
bated with the virus, the number of phages bound to the
virus was reduced gradually in a dose-dependent manner.
At 1 mM concentration of the peptides, the phage binding
was almost completely inhibited (Figure 8). The control
peptide does not possess any inhibitory effects on phage
binding to AIV.
Interaction between C-P1 peptide and HAt/NA protein by 
yeast two hybrid assay
The yeast two-hybrid assay was employed to validate the
HA-P1 interaction and also to identify any interaction
between NA-P1. To eliminate the false positive results (the
possibility of Binding Domain (BD)-P1, Activation
Domain (AD)-HAt and AD-NA fusion proteins themselves
bringing about activation of the reporter genes), various
Effect of peptides against NDV Figure 6
Effect of peptides against NDV. Cyclic, linear and FP-P1 
at 100 μM concentrations were analysed for their inhibitory 
ability against NDV in embryonated chicken eggs. Viral titers 
in the allantoic fluid were measured as HA units. Results are 
shown as the mean of three independent experiments and 
error bars represent the standard deviation of the mean. 
None of the peptides showed a statistically significant result 
(ANOVA, p = 0.596).
Table 2: Inhibitory ability of the cyclic and linear peptides against 
the hemagglutination activity of the avian influenza virus H9N2.
Inhibitory Molecule Minimum Inhibitory Concentration*
Cyclic Peptide 100 μM
Linear Peptide 100 μM
Fusion Phage 1013 pfu/100 μl
* Minimum concentration of peptides or phage required to inhibit the 
hemagglutination activity of 32 HAU of AIV
Antibody-phage competition assay Figure 7
Antibody-phage competition assay. The phage com-
petes with polyclonal antibodies for binding site on AIV, sug-
gesting they may share common binding sites. Experiments 
were done in triplicates and the error bars represent the 
standard deviation of the mean. *, statistical significance (P < 
0.05)Virology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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combinations of the recombinant plasmids along with
the parental vector were co-transformed into the yeast
competent cells (Table 3). Three independent clones from
each co-transformation were analysed for the activation of
the β-galactosidase (β-gal) reporter genes. As shown in
Table 3, the co-transformed parental vectors did not show
any β-gal activities. When BD-P1 and AD-HAt or BD-P1
and AD-NA fusion constructs were co-transformed sepa-
rately along with their respective parental vectors, no β-gal
activity was detected either. The co-transformed BD-P1
and AD-HAt as well as BD-P1 and AD-NA showed com-
paratively high level of β-gal activity (25 and 3.5 Miller
Units respectively). This observation showed that the P1
peptide bind with both with HA glycoprotein as well as
the NA glycoprotein. The P1 interaction with HA glyco-
protein support the previous experimental observation of
hemagglutination inhibition. As the yeast two-hybrid
assay provided ambiguous result regarding the NA-P1
interaction, further experimental analysis (co-immuno-
precipitation) was carried out.
HAt-P1, NA-P1 interaction study by Co-
immunoprecipitation
In order to verify the binding ability of the peptide P1
with HAt and NA proteins through Co-IP method, these
three proteins were initially synthesised by in vitro tran-
scription and translation methods. The P1 peptide was
mixed either with the HAt protein or NA protein sepa-
rately to allow the binding overnight or after incubation,
the HA or NA protein present in the mixture was immu-
noprecipitated by anti-AIV polyclonal serum. After three
rounds of washing, the bound P1 was detected by anti-His
monoclonal antibodies (Novagen, USA). The P1 peptide
was detected only in the HA complex (Figure 9). There
was no P1 peptide visible in the NA complex (data not
shown). This experiment confirmed the interaction of the
P1 peptide to the HA protein.
Peptide Toxicity
To analyse the cellular toxicity properties of the peptides
and fusion phages, MDCK cells were exposed to 100 μM
of cyclic, linear peptides or 1013 pfu/100 μl of FP-P1 for 24
hrs and the cell viability was determined by MTT assay.
There was no significant difference (Students t test, P >
0.05) observed in the cell viability of control and peptide
treated cells (Figure 10).
Discussion
Emerging and re-emerging infectious diseases remain to
be one of the major causes of death worldwide. The cur-
rent outbreak of avian influenza viruses is a major global
Peptide-phage competition assay Figure 8
Peptide-phage competition assay. The peptides com-
petes with the fusion phage FP-P1 for binding sites on AIV, 
suggesting that peptides displayed on the fusion phage FP-P1, 
and not other parts of the phage, binds to the AIV. Experi-
ments were performed in triplicates and the error bars rep-
resent the standard deviation of the mean.
Table 3: P1: HAt/NA interactions in the yeast two-hybrid system
DBD Vectorsa AD Vectorsa β-gal activityb
Background
BD AD 0.05
BD-P1 AD 0.07
BD AD-HAt 0.05
BD AD-NA 0.03
P1:HAt/NA interactions
BD-P1 AD-HAt 25
BD-P1 AD-NA 3.5
apHyblex/Zeo and pYESTryp2 are vectors encoding the LexA DNA 
binding domain (BD) and B42 transcriptional activation domain (AD), 
respectively.
bAverage β-gal activity (Miller Units) of 3 independent colonies for 
each co-transformation (The SD value is not shown as there was very 
little variation between repeated experiment).
Western blot analysis of immunoprecipitated HAt-P1 com- plex Figure 9
Western blot analysis of immunoprecipitated HAt-
P1 complex. In vitro translated NA protein or HAt protein 
was mixed with P1 peptide and the complex was co-immu-
noprecipitated using anti-AIV serum and the eluted complex 
was analysed by SDS-15% PAGE, electrotransferred to a 
nitrocellulose membrane and probed with anti-His mono-
clonal antibody (Novagen, USA). Lane 1: HAt and P1 com-
plex; lane 2: NA and P1 complex; For control, in vitro 
translated NA or HAt mixed with control peptide 
SWGEYDM and detected using anti-His antibodies. Lane 3: 
HAt and Control peptide complex; Lane 4: NA and control 
peptide complex; Lane 5: in vitro translated P1 peptide (~12 
kDa). The arrow indicates the precipitated P1 protein in the 
HAt-P1 complex and the in vitro translated P1 peptide.Virology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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concern due to the increasing number of fatalities among
the poultry as well as human cases. Its highly mutative
nature makes the current antiviral drugs not very effective.
Therefore, there has been a constant need for broad-spec-
trum antiviral drugs against the currently circulating
human as well as avian strains.
In this study, a phage displayed peptide library was used
to select anti-viral peptides against the AIV H9N2. At the
end of biopanning, four different peptide sequences were
identified. Matching of these peptide sequences with pro-
tein sequences in the protein data banks (Swiss Prot and
NCBI) showed no significant homology with any protein
sequences. It is possible that these peptides might mimic
a discontinuous binding site in which amino acids are
brought from different positions of a protein to form an
essential contact area with the virion [23,24]. The lack of
antiviral activity by the control peptide as well as the wild
type phage suggests that the antiviral property of the pep-
tides is specific to those peptides and neither a general
property of any oligomeric peptide or wild type M13 bac-
teriophages nor based on charge or hydrophobic interac-
tions. The peptide phage competition assay proved that
the peptide displayed on the phage surface not the other
parts of the phage binds to the virus.
Among the four different fusion phages isolated from the
phage display library, the phage displaying the sequence
NDFRSKT was selected for further analysis as it repre-
sented highest number of clones in the final round of bio-
panning. Besides, the peptides LPYAAKH, ILGDKVG, and
QHSTKWF showed negligible or no anti-viral activity
(data not shown); therefore, no further analyses on these
peptides were carried out.
The in ovo model has been previously employed success-
fully by our group Ramanujam et al. [25] and Song et al.
[26] to study the inhibitory effect of anti-viral molecules
against the Newcastle disease virus and influenza virus
respectively. Therefore, the antiviral activity of the syn-
thetic peptides and the fusion phages themselves (or sim-
ply denoted as inhibitory peptides hereafter) were
investigated in embryonated chicken eggs. All the pep-
tides showed good anti-viral properties against AIV and
interestingly there was no significant anti-viral effect
found against NDV strain AF2240. Pre-treatment with the
peptides or fusion phages reduced the AIV titre manifold
(from 2 fold to 6 fold based on the type of peptide and
number of days of treatment) in the infected allantoic
fluid. But the post-infection treatment failed to protect the
embryo (data not shown). However, it should be noted
that the peptide was injected only once in the study and
besides, the amino acids of the peptide were of L-isomers
which are more prone to protease degradation inside the
allantoic cavity.
Nevertheless, both cyclic and linear forms of peptides as
well as the fusion phages proved their worth as antiviral
molecules in varied potential levels. Among them, the
cyclic peptide possessing the sequence CNDFRSKTC
showed higher antiviral properties. The reason maybe its
small size (only 9 amino acids in length for cyclic peptide)
which helps its easy access to the respective binding site
on the target molecule. Moreover, the cyclic peptides pos-
sess a stable structure due to the disulfide bond formed
between the flanked cysteine residues which help to attain
a stable interaction at a short time when compared to the
linear peptides [27,28]. Small peptide molecules have
been used in the development of peptide based vaccines
for melanoma [29], inhibitors against HIV [30], Dengue
and West nile virus [31] and anti-angiogenic in the treat-
ment of angiogenesis related diseases [32].
As whole virus particles were used in biopanning experi-
ments, in principle, the selected peptides might interact
with any of the three surface proteins such as HA, NA and
M2. Since these inhibitory peptides possess strong anti-
viral activity when used at pre-infection not at post-infec-
tion and also inhibit the hemagglutination, it can be
deduced that the peptides (NDFRSKT and CNDFRSKTC)
prevent the viral replication by inhibiting the attachment
or entry of the virus into the target cells. There are many
studies on the targeting of the conserved region of the HA
protein. Recently, Jones et al. [33] identified that a well
known cell-penetrating peptide, derived from the fibrob-
last growth factor 4 (FGF-4) signal sequence, possesses the
broad-spectrum anti-influenza activity, which act by
blocking the entry of virus through the HA protein inter-
action.
Neuraminidase (NA) is the second most abundant surface
protein and responsible for the neuraminidase activity of
the virus. It is important both for its biological activity in
In vitro toxicity of inhibitory peptides Figure 10
In vitro toxicity of inhibitory peptides. MDCK cells 
were treated with 100 μM of C-P1 or L-P1 or 1014 pfu/ml of 
FP-P1 and the cell viability was analysed by MTT assay after 
24 hrs of incubation (mean of three experiments +/- SD). No 
statistically significant differences in cell viability were 
observed (Students t test, P > 0.05).Virology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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removing sialic acid from glycoproteins and as a major
antigenic determinant that undergoes variation. At
present, the neuraminidase inhibitors such as zanamivir
and oseltamivir are preferentially used for the treatment
and prophylaxis of influenza [9], as the NA protein is less
mutative when compared with HA. There are three recep-
tor binding sites, two at the distal ends of both HA subu-
nits and the third one in the NA protein [34] and changes
in both HA and NA glycoproteins will affect the fitness of
the virus [35]; therefore, the effect of peptide on the neu-
raminidase protein was assessed. Unfortunately, this
experiment showed a negative result for the fusion phages
and cyclic peptides and partial inhibition result at very
high concentration of linear peptide (~35% inhibition at
1000 μM). The latter inhibition may be nonspecific due to
the increased ability of the linear molecules to attain a
structure that facilitates the binding with NA molecule or
merely based on hydrophobicity and charge.
The HA-P1 and NA-P1 interaction was further analysed by
the yeast two-hybrid system and co-immunoprecipita-
tion. There has been a problem in amplifying the full
length clone of HA gene for the past few years in our lab-
oratory. The same problem has also been reported in few
other laboratories working with the same strain in this
region. The 3' end of the vRNA could not be amplified
either by primer designed for conserved region or gene
specific region based on other similar strain's sequence.
The HA protein should be cleaved into two disulfide
linked HA1 and HA2 in order to be infectious. The C-termi-
nal HA2 region is very important as it accounts for the
entry of the virus into the host cell and thus serves as a
fusion protein [36]. Therefore, the truncated HA protein
representing C-terminal end (278 aminoacids) of the full
length HA protein was used for the yeast two-hybrid and
co-immunoprecipitation experiments. The yeast hybrid
assay turned positive for the both HA and NA proteins
although the β-galactosidase activity for HA is nearly 7
fold higher than the NA. Although, there was negligible or
no interaction between NA and P1 as per the results of NA
inhibition test and co-immunoprecipitation results, the
yeast two-hybrid experiment showed a significant NA-P1
interaction which is almost 100 times higher than the
control. So, NA-P1 interaction cannot be simply ignored
and further investigations are required to analyse the kind
of interaction between the NA glycoproteins and peptide
P1. But, the HA and P1 interaction has been clearly dem-
onstrated without any doubt in all the performed experi-
ments.
Conclusion
Taking all together, this study has identified a novel anti-
viral molecule which inhibits the avian influenza virus
infection by interacting with the surface glycoprotein HA
and preventing its attachment to the host cell. To our
knowledge, the selected peptide is the only antiviral pep-
tide amongst the currently identified anti-viral peptides
with 7 or 9 amino acids in length. This short sequence will
be an added advantage for commercialisation purpose as
it can greatly reduce the cost of production. However,
additional studies are required to define the broad-spec-
trum activity of the peptide against various strains includ-
ing the currently circulating potential pandemic strains
such as H1N1 and H5N1 as well as its diagnostic poten-
tial.
Methods
Viruses, Cells and viral purification
Avian influenza A/Chicken/Iran/16/2000(H9N2), a low
pathogenic avian influenza virus and Newcastle disease
virus (NDV) strain AF2240 was kindly provided by Abdul
Rahman Omar. Viruses were propagated in 9-day old spe-
cific pathogen free embryonated chicken eggs. The allan-
toic fluid was clarified and the viruses were purified and
concentrated as explained previously [25]. The virus titer
was determined by hemagglutination test (HA) and the
protein concentration of the purified virus was deter-
mined by Bradford assay [37].
Selection of peptides against AIV sub-type H9N2
The virus (15 μg/ml; 100 μl) was coated onto a microtiter
plate well with NaHCO3 (0.1 M, pH 8.6) buffer overnight
at 4°C. Streptavidin (0.1 mg/ml; 100 μl) was also coated
and used as positive control. Phages from a disulfide con-
strained 7-mer  phage display random peptide library
(New England Biolabs, USA) were biopanned as
explained by the manufacturer. The amplified phages
from the first round of biopanning were used for the sec-
ond round of biopanning. Totally four rounds of biopan-
ning were carried out. Phage titration was carried out
according to the method described by Sambrook et al
[38]. Phages were propagated in Escherichia coli (E. coli)
host cells grown in LB broth (1 L). The phage particles
were precipitated by PEG and purified through cesium
chloride density gradient centrifugation as descried by
Smith and Scott [39].
Sequence analysis of phagemids
The nucleotide sequence encoding the hypervariable hep-
tapeptide region of pIII coat protein of M13 phage was
sequenced by 1st  Base Laboratories Sdn Bhd, Kuala
Lumpur, with the -96 gIII sequencing primer 5' CCC TCA
TAG TTA GCG TAA CG 3'. Sequence analyses such as com-
parison with wild type M13 phage pIII coat protein and
prediction of amino acid sequences were performed with
the free bioinformatics software package, SDSC biology
workbench 3.2.
Estimation of binding abilities of selected phages
The avian influenza viruses were coated (5 or 10 μg/ml;
200 μl) on a microtiter plate with TBS buffer overnight at
4°C. The excess target was removed and blocked withVirology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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blocking buffer (milk diluent KPL, USA) for 2 h at 4°C.
The plate was then washed with 1× TBST (TBS and 0.5%
[v/v] Tween 20). Selected phages were added into the well
at the concentration of either 1012 pfu/ml or 1011 pfu/ml
and incubated for 2 h at room temperature. The plate was
again washed 6 times with 1× TBST. HRP-conjugated anti-
M13 antibody (Pharmacia, USA) was diluted into 1:5000
with blocking buffer and added 200 μl into each well,
incubated at room temperature for 1 h with agitation. It
was then washed 6 times with 1 × TBST as explained
above. 200 μl substrate solution (22 mg ABTS in 100 ml
of 50 mM sodium citrate and 36 μl of 30% H2O2, pH 4.0)
was added to each well and incubated for 60 min. Then
the plate was read using a microplate reader (Model 550,
BioRad, California, USA) at 405–415 nm.
Peptides
Peptides were synthesised at GL Biochem, Shanghai,
China with more than 98% purity. The peptides con-
tained the sequences as mentioned in Table 4.
Cytotoxicity test by MTT assay
MDCK cells (~5000 cells/well) were grown on 96 well
plates for 24 h. The media was replaced by serially diluted
peptides or fusion phages and incubated again for 48 h.
The culture medium was removed and 25 μl of MTT [3-
(4,5-dimethylthiozol-2-yl)-3,5-dipheryl tetrazolium bro-
mide] (Sigma) was added and incubated at 37°C for 5 h.
Then 50 μl of DMSO was added to solubilised the forma-
zan crystals and incubated for 30 mn. The optical density
was measured at 540 nm in an microplate reader (Model
550, BioRad, USA).
Virus yield reduction assay in egg allantoic fluid
The avian influenza A/Chicken/Iran/16/2000 (H9N2)
virus suspension containing 8 or 16 HAU/50 μl was
mixed with various concentrations of linear/cyclic pep-
tides or fusion phages (50 μl) for 1 h at room temperature.
This mixture was then injected into the allantoic cavity of
9 day-old embryonated chicken eggs and incubated at
37°C for 3 days. After incubation, the eggs were chilled for
5 h, the allantoic fluids were harvested and titrated by
hemagglutination (HA) assay. As control, virus mixed
with nonspecific peptides or wild phages were injected
into the eggs.
Hemagglutination inhibition assay
The hemagglutination inhibition (HI) assay was carried
out as originally explained by Ramanujam et al., (2002)
with slight modifications to evaluate the ability of the
peptides/fusion phages to inhibit the viral adsorption to
target cells. Linear/Cyclic peptides or fusion phages (50
μl) in serial two-fold dilutions in PBS were mixed with
equal volume of influenza solution (8 HAU/50 μl) and
incubated at room temperature for 1.5 h. Subsequently,
50 μl of 0.8% red blood cells were added to the above
mixture and further incubated at room temperature for 45
min.
Neuraminidase inhibition assay
The neuraminidase inhibition assay was carried out to test
the ability of the peptide to inhibit the viral neuramini-
dase activity, as explained in Aymard-Hendry et al. [40]
with slight modifications. The substrate used in this exper-
iment was neuraminlactose rather than feutin.
Preparation of Anti-AIV sera
Six month old New Zealand white rabbits were used for
the production of polyclonal antibodies. Rabbits were
pre-bleeded before injection. 50 μg of purified virus in
PBS together with equal amount of Freund's adjuvant was
injected into the rabbit subcutaneously. Subsequent
booster injections were done with Freund's incomplete
adjuvant. Injections were done for every 4 weeks, with
bleeds 7 – 10 days after each injection. Antibodies were
purified with Montage® antibody purification kits (Milli-
pore, USA) as instructed by the manufacturer.
Antibody-Phage competition assay
Wells were coated with AIV subtype H9N2 (20 μg/ml; 100
μl) as the aforesaid conditions of biopanning. A mixture
of purified polyclonal antibodies (1:500 dilutions; 100
μl) raised against AIV sub-type H9N2 and a series of dif-
ferent concentrations of phage FP-P1 (108 – 1012 pfu; 100
μl) were prepared in eppendorf tubes. After blocking the
wells, these mixtures were added and incubated at room
temperature for 1 h. Wells were washed and bound
phages were eluted and titrated. As for the positive con-
trol, AIV coated wells were incubated with the phage with-
out the presence of the polyclonal antibodies.
Peptide-Phage competition assay
The peptide – phage competition assay was performed to
assay the inhibitory effects of synthetic peptides with its
phage counterparts (FP-P1). AIV H9N2 was coated on a
multi-well plate at the aforesaid conditions of biopanning
and incubated with different concentrations of either lin-
ear of cyclic peptides (0.0001 – 1000 μM) in binding
buffer for 1 h at 4°C. After 1 h incubation, phage FP-P1
(1010 pfu/100 μl) was added and incubated at 4°C for
another 1 h. Wells were then wash 6 times with TBST and
Table 4: Peptides used in this study
Name of the peptide Sequence of the peptide
L-P1 (Linear Peptide) NDFRSKT
C-P1(Cyclic Peptide) CNDFRSKTC
Control Peptide CSWGEYDMCVirology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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the bound phages were eluted and titered. [Percentage of
phage binding = (number of phage bound in the presence
of peptide competitor/number of phage bound in the
absence of peptide competitor) × 100].
In vivo study of protein-protein interactions: Yeast two-
hybrid assay
Cloning of HAt, NA and P1 genes into pYESTrp2 and pHybLex/Zeo 
vectors
The NA and truncated HA protein (HAt) genes of AIV sub-
type H9N2 were amplified by Reverse Transcription-
Polymerase Chain Reaction (RT-PCR) from the viral RNA
using the primers pY-HAt-F & R and pY-NA-F & R, men-
tioned in Table 5. The NA gene carried the recognition
sites for EcoRI and XhoI whereas the HAt gene carried the
recognition sites KpnI and XhoI restriction enzymes in
their forward and reverse primers respectively. The pep-
tide gene (P1) was amplified including the N1 domain of
the P3 protein of the recombinant phage using the primer
pH-P1-F & R (Table 5) from the ssDNA genome of the
phage as the peptide is displayed as a fusion protein to
this domain of the P3 protein. The P1 gene carried the rec-
ognition sites for EcoRI and XhoI restriction enzymes in its
forward and reverse primers respectively. The amplified
HAt and NA genes were ligated into pYESTrp2 vectors sep-
arately (Invitrogen, USA) and the P1 gene was cloned into
pHybLex/Zeo (Invitrogen, USA) vector. The resultant
clones were named as pY-HA, pY-NA and pH-P1 respec-
tively. The constructs were sequenced using the primers
pYESTrp2-F & R and pHybLex/Zeo-F & R (Table 5) to
check the reading frame and for the absence of mutations.
The Saccharomyces cerevisiae strain L40 was then co-trans-
formed with the recombinant plasmids using lithium ace-
tate method and the transformants were analysed for their
β-galactosidase activity as explained in Ausubel et al. [41].
In vitro study of protein-protein interactions
Construction of recombinant pC-HAt, pC-NA and pC-P1 and in vitro 
transcription and translation
The HAt and NA gene of AIV strain H9N2 as well as the
recombinant peptide gene P1 was amplified from pY-HA,
pY-NA and pH-P1 respectively as templates using the
primers pC-HA-F & R, pC-NA-F & R and pC-P1-F & R
respectively (Table 5) and cloned into the pCITE2a vector.
The in vitro transcription and translation was performed
in a single tube in a reaction mixture (15 μl) containing
circular recombinant plasmid (1 μg), TNT® Quick Master
Mix (12 μl; Promega, USA), Methionine (0.3 μl, 1 mM;
Promega, USA). The above mixture was incubated at
30°C for 90 min. The translated products (3 μl) were elec-
trophoresed on 15% SDS-PAGE and then transferred by
electrophoresis for 1 h onto a nitrocellulose membrane.
They were detected with anti-His antibody for P1 protein
and HAt/NA proteins were detected with the polyclonal
antibodies raised against the AIV sub-type H9N2 in rab-
bit.
Co-immunoprecipitation
Co-immunoprecipitation was performed using the Pierce®
Co-IP kit (Thermo Scientific, USA) as per the instructions
given by the manufacturer. Briefly, the bait and pray com-
plex was prepared separately by mixing the HAt or NA
with His-conjugated P1 peptide. The complex was precip-
itated using purified anti-AIV polyclonal antibodies,
which were immobilised on antibody coupling resin. The
peptide P1 in the eluted co-immunoprecipitated complex
was analysed by Western blotting using anti-His mono-
clonal antibodies (Novagen, USA) and detected with
Amersham® ECL® western blotting detection reagents (GE
Healthcare, USA).
Table 5: Oligonucleotides used to amplify the NA, HAt and P1genes
Primers Sequence
pY-NA-Fa 5' CATAGAATTCGCAAAAGCAGGAGT 3'
pY-NA-R 5' TATCGCTCGAGAGTAGAAACAAGGAG 3'
pY-HAt-F 5' ATTTAAGGTACCGACAGCCATGGA 3'
pY-HAt-R 5' ATGCTGCTCGAGTATACAAATGTTGC 3'
pH-P1-F 5' AGCCTGGAATTCATGAAAAAATTA 3'
pH-P1-R 5' ATCGAACTCGAGATTTTCAGGGAT 3'
pHybLex/Zeo-F 5' AGGGCTGGCGGTTGGGGGTTATTCGC 3'
pHybLex/Zeo-R 5' GAGTCACTTTAAAATTTGTATACAC 3'
pYESTrp2-F 5' GATGTTAACGATACCAGCC 3'
pYESTrp2-R 5' GCGTGAATGTAAGCGTGAC 3'
pC-HA-F 5'ATTTAAGGATCCGAGAGCCATGGA 3'
pC-HA-R 5'ATGCTGCTCGAGTTATATACAAATGTTGC 3'
pC-NA-F 5'CATAGAATTCGCAAAAGCAGGAGT 3'
pC-NA-R 5'TATCGCTCGAGAGTAGAAACAAGGAG 3'
pC-P1-FP 5'AGCCTGGAATTCATGAAAAAATTA 3'
pC-P1-RP 5'CTCACTCGAGACATTTTCAGGGA 3'
aIn all of the above mentioned oligonucleotides, the suffixes F and R refers Forward and Reverse primers respectivelyVirology Journal 2009, 6:74 http://www.virologyj.com/content/6/1/74
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Statistical Analysis
All experiments were carried out in triplicate and are rep-
resentative of at least three separate experiments. The
results represent the means ± standard deviations or
standard error means of triplicate determinations. Statisti-
cal significance of the data was determined by independ-
ent t test or one-way ANOVA method using SPSS software.
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